Ethnic differences in creatinine kinetics in a New Zealand end-stage kidney disease cohort

Nephrology ◽  
2013 ◽  
Vol 18 (3) ◽  
pp. 222-228 ◽  
Author(s):  
Tina Y-T Sun ◽  
Katie E Lee ◽  
Jamie C Kendrick-Jones ◽  
Mark R Marshall
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
Ethnic Differences ◽  
End Stage Kidney Disease ◽  
Creatinine Kinetics ◽  
End Stage

scholarly journals Absolute risk and risk factors for stroke mortality in patients with end-stage kidney disease (ESKD): population-based cohort study using data linkage

BMJ Open ◽  
2019 ◽  
Vol 9 (2) ◽  
pp. e026263 ◽  
Author(s):  
Nicole Louise De La Mata ◽  
Maria Alfaro-Ramirez ◽  
Patrick J Kelly ◽  
Philip Masson ◽  
Rustam Al-Shahi Salman ◽  
...  
Keyword(s):  
Risk Factors ◽  
New Zealand ◽  
Kidney Disease ◽  
Cerebrovascular Disease ◽  
Cumulative Incidence ◽  
Data Linkage ◽  
Polycystic Kidney ◽  
End Stage Kidney Disease ◽  
End Stage ◽  
Stroke Death

IntroductionPeople with end-stage kidney disease (ESKD) have up to 30-fold higher risk of stroke than the general population.ObjectiveTo determine risk factors associated with stroke death in the ESKD population.MethodsWe identified all patients with incident ESKD in Australia (1980–2013) and New Zealand (1988–2012) from the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) registry. We ascertained underlying cause of death from data linkage with national death registries and risk factors from ANZDATA. Using a competing risks multivariable regression model, we estimated cumulative incidence of stroke and non-stroke deaths, and risk factors for stroke deaths (adjusted sub-HR, SHR).ResultsWe included 60 823 people with ESKD. There were 941 stroke deaths and 33 377 non-stroke deaths during 381 874 person-years of follow-up. Overall, the cumulative incidence of stroke death was 0.9% and non-stroke death was 36.8% 5 years after starting ESKD treatment. The risk of stroke death was higher at older ages (SHR 1.92, 95% CI 1.45 to 2.55), in females (SHR 1.41, 95% CI 1.21 to 1.64), in people with cerebrovascular disease (SHR 2.39, 95% CI 1.99 to 2.87), with ESKD caused by hypertensive/renovascular disease (SHR 1.39, 95% CI 1.09 to 1.78) or polycystic kidney disease (SHR 1.38, 95% CI 1.00 to 1.90), with earlier year of ESKD treatment initiation (SHR 1.93, 95% CI 1.56 to 2.39) and receiving dialysis (transplant vs haemodialysis SHR 0.27, 95% CI 0.09 to 0.84).ConclusionPatients with ESKD with higher risk of stroke death are older, women, with cerebrovascular disease, with hypertensive/renovascular or polycystic kidney disease cause of ESKD, with earlier year of ESKD treatment and receiving dialysis. These groups may benefit from targeted stroke prevention interventions.

Ethnic differences in illness intrusiveness among patients with end stage kidney disease

2018 ◽  
Vol 109 ◽  
pp. 123
Author(s):  
M. Novak ◽  
T. Ahmed ◽  
N. Edwards ◽  
A. Ayub ◽  
C. Richardson ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Ethnic Differences ◽  
Illness Intrusiveness ◽  
End Stage Kidney Disease ◽  
End Stage

Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand

2009 ◽  
Vol 24 (9) ◽  
pp. 1719-1726 ◽  
Author(s):  
Nigel I. T. Orr ◽  
Stephen P. McDonald ◽  
Steven McTaggart ◽  
Paul Henning ◽  
Jonathan C. Craig
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
End Stage Kidney Disease ◽  
End Stage

Cause of death for people with end-stage kidney disease withdrawing from treatment in Australia and New Zealand

2020 ◽  
Author(s):  
Victor Khou ◽  
Nicole L De La Mata ◽  
Rachael L Morton ◽  
Patrick J Kelly ◽  
Angela C Webster
Keyword(s):  
New Zealand ◽  
Kidney Disease ◽  
Confidence Interval ◽  
Treatment Modality ◽  
Causes Of Death ◽  
Mortality Rates ◽  
Service Planning ◽  
Treatment Withdrawal ◽  
End Stage Kidney Disease ◽  
End Stage

Abstract Background Withdrawal from renal replacement therapy is common in patients with end-stage kidney disease (ESKD), but end-of-life service planning is challenging without population-specific data. We aimed to describe mortality after treatment withdrawal in Australian and New Zealand ESKD patients and evaluate death-certified causes of death. Methods We performed a retrospective cohort study on incident patients with ESKD in Australia, 1980–2013, and New Zealand, 1988–2012, from the Australian and New Zealand Dialysis and Transplant registry. We estimated mortality rates (by age, sex, calendar year and country) and summarized withdrawal-related deaths within 12 months of treatment modality change. Certified causes of death were ascertained from data linkage with the Australian National Death Index and New Zealand Mortality Collection database. Results Of 60 823 patients with ESKD, there were 8111 treatment withdrawal deaths and 26 207 other deaths over 381 874 person-years. Withdrawal-related mortality rates were higher in females and older age groups. Rates increased between 1995 and 2013, from 1142 (95% confidence interval 1064–1226) to 2706/100 000 person-years (95% confidence interval 2498–2932), with the greatest increase in 1995–2006. A third of withdrawal deaths occurred within 12 months of treatment modality change. The national death registers reported kidney failure as the underlying cause of death in 20% of withdrawal cases, with other causes including diabetes (21%) and hypertensive disease (7%). Kidney disease was not mentioned for 18% of withdrawal patients. Conclusions Treatment withdrawal represents 24% of ESKD deaths and has more than doubled in rate since 1988. Population data may supplement, but not replace, clinical data for end-of-life kidney-related service planning.

Sign in / Sign up

Export Citation Format

Share Document